Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
On January 5, 2022, amendments came into force amending the Food and Drug Regulations to allow practitioners to request access to restricted drugs through the Special Access Program (SAP)...
On January 5, 2022, amendments came into force amending
the Food and Drug Regulations to allow
practitioners to request access to restricted drugs through the
Special Access Program (SAP), which was previously prohibited.
Restricted drugs are controlled substances that are listed in
the
Schedule to Part J of the Food and Drug
Regulations which includes, for example, certain
amphetamines and lysergic acid diethylamide (LSD). Health
Canada revised its Special Access Program for drugs: Guidance
document for industry and practitioners to reflect these
amendments. The Guidance also addresses the need for an
exemption under the Controlled Drugs and Substances
Act, if a restricted drug is authorized for sale through the
SAP.
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
